Deruxtecan is a chemical compound and a derivative of exatecan that acts as topoisomerase I inhibitor.
It is available linked to specific monoclonal antibody (antibody–drug conjugate), such as: Trastuzumab deruxtecan. It is licensed for the treatment of breast cancer or gastric or gastroesophageal adenocarcinoma. Patritumab deruxtecan, an experimental antibody–drug conjugate to treat non-small-cell lung cancer. Ifinatamab deruxtecan, an experimental anti-cancer treatment. Datopotamab deruxtecan (Datroway), used for the treatment of breast cancer
References